NuVation Bio Inc.
Clinical trials sponsored by NuVation Bio Inc., explained in plain language.
A clinical-stage biopharmaceutical company developing therapies for metabolic diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a common heartburn pill change how a cancer drug works? Results expected Feb 2027 (estimated)
- New hope for Hard-to-Treat cancers: NUV-1511 enters human trials Results expected Mar 2027 (estimated)
-
New hope for brain tumor patients when standard drug fails
Disease control Not yet recruitingThis study tests an experimental drug called safusidenib in people with a slow-growing brain tumor (IDH1-mutant glioma) whose tumor got worse while on the standard drug vorasidenib. Up to 40 participants take safusidenib pills twice daily to see if the tumor shrinks or stops grow…
Phase 2 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Targeted pill aims to stall a common brain Tumor's growth
Disease control Not yet recruitingThis study tests whether the experimental drug safusidenib can slow or stop the growth of a type of slow-growing brain tumor called grade 2 glioma that has a specific genetic change (IDH1 mutation). Participants have had surgery but no other treatments like chemotherapy or radiat…
Phase 3 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Can a common heartburn pill change how a cancer drug works?
Knowledge-focused Not yet recruitingThis study in healthy adults tests whether famotidine, a common heartburn medication, changes how the body absorbs and processes taletrectinib, an experimental cancer drug. Participants receive taletrectinib alone or with different doses and timings of famotidine to compare drug …
Phase 1 • Sponsor: Nuvation Bio Inc. • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC